![Page 1: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/1.jpg)
State of the Art: Gestational Trophoblastic Lesions
Treatment beyond single agents
Barry Hancock(Sheffield, UK)
International Gynecologic Society Meeting 2006
![Page 2: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/2.jpg)
![Page 3: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/3.jpg)
![Page 4: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/4.jpg)
![Page 5: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/5.jpg)
Which group of patients?
Risk (WHO score, Dutch classification)
Prognosis (Hammond)
Stage (Song, FIGO)
Choriocarcinoma risk (Japan)
Criteria for treatment
![Page 6: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/6.jpg)
Two scenarios
Single agent resistance
‘High’ risk disease
![Page 7: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/7.jpg)
Single agent resistance
Alternative single agent
Combination chemotherapy (EMA-CO, MAC, EA etc)
![Page 8: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/8.jpg)
Single agent resistance
For ‘low’ risk non-metastatic disease single agent chemotherapy is 60-90% successful
Second line multi-agent therapy is virtually always (>95%) successful in dealing with single agent resistance
![Page 9: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/9.jpg)
Benefits
Is intensive chemotherapy necessary for all high risk patients?
Higher CR
Less salvage treatment
Shorter treatment period
Risks
Over treatment
Higher financial costs
More toxicity
![Page 10: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/10.jpg)
What is the evidence base?
One randomized controlled trial
Lots of small-moderate sized series
One retrospective comparative study
![Page 11: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/11.jpg)
Primary treatment for high risk GTNMAC (MTX, dactinomycin, chlorambucil or cyclophosphamide)
EMA-CO (etoposide, MTX, dactinomycin, cyclophosphamide, vincristine)
EMA/MEA
CHAMOCA (cyclophosphamide, hydroxyurea, dactinomycin, MTX, vincristine, doxorubicin)
CHAMOMA (+ melphalan)
FME (FU, MTX, etoposide)
Previously single agent MTX!
![Page 12: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/12.jpg)
Primary remission rates in high risk GTN
MAC 63-80%
CHAMOCA 82%
MAC vs CHAMOMA 73% vs 65%
EMA-CO >80%
EMA/MEA/FME 75-80%
![Page 13: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/13.jpg)
Salvage treatment in high risk GTN
EMA-EP (EMA - etoposide, cisplatin)
BEP (bleomycin, etoposide, cisplatin)
CEC (cyclophosphamide, etoposide, cisplatin)
MISC (high dose chemotherapy, carboplatin/paclitaxel, paclitaxel/etoposide and paclitaxel/cisplatin doublet)
![Page 14: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/14.jpg)
Salvage treatment
20-60% success
![Page 15: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/15.jpg)
Surgery
![Page 16: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/16.jpg)
Toxicity
EP-EMA
CHAMOCA
EMA-CO
MAC
EMA/MEA/FME
![Page 17: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/17.jpg)
Toxicity
Multi-treated patients
Potential mortality whatever is chosen
![Page 18: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/18.jpg)
Acute toxicityAlopecia +++++
Neutropenia ++++
Anemia +++
Nausea/vomiting ++
Stomatitis ++
Neutropenic sepsis ++
Thrombocytopenia +
![Page 19: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/19.jpg)
Long-term toxicity
Increased second malignancy
Premature menopause
Unknown!
![Page 20: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/20.jpg)
Staff Nurse Ellen Zitek in BBCs ‘Casualty’ Treated for ‘cancer’ after a molar pregnancy
![Page 21: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/21.jpg)
![Page 22: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/22.jpg)
FIGO SCORING 0 1 2 4
Age < 40 40 - -
Antecedent pregnancy
Mole Abortion Term -
Interval months from index pregnancy
< 4 4 - < 7 7 - < 13 13
Pre-treatment serum hCG (IU/L)
< 103 103 - < 104 104 - < 105 105
Largest tumour size (including uterus) cm
< 3 3 - < 5 5 -
Site of metastases Lung Spleen, kidney
Gastro-intestinal
Liver, brain
Number of metastases - 1-4 5-8 > 8
Previous failed chemotherapy
- - Single drug 2 or more drugs
![Page 23: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/23.jpg)
Chemotherapy for High Risk GTN(Sheffield UK)
Day 1 MTX 100mg/m2 iv Folinic acid rescue
Day 8, 9, 10 Dactinomycin 500µg iv Etoposide 100mg/m2 iv
et seq 7 days
M/AE
![Page 24: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/24.jpg)
Sheffield Trophoblast Centre, UK
1986-2005Registration 8211
459 (6%)Persistent GTN
Low risk High risk
54 (12%) MAE
79 8
405 (88%)MTX
Resistant
AEA
![Page 25: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/25.jpg)
Methotrexate resistant GTN
CR 78 (99%)
EA 79 Refractory 1
1 †
Median follow-up 8 years
Late deaths 0
2nd malignancy 0Further pregnancy >60%
![Page 26: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/26.jpg)
High risk GTNMEA 54
CR 42 (78%)
Refractory12 2 other
TAH 5 5 CEC
24 1+7
49 (91%) alive and well
Median follow-up 8.5 yearsLate deaths 0
Further pregnancy >60%2nd malignancy 0
1 4 †
![Page 27: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/27.jpg)
Cure rates in GTN1st line Salvage
Low risk
(70-90%)75% 99%
High risk
(10-30%)75% 95%
Overall 98% cure
![Page 28: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/28.jpg)
Conclusion The majority of patients are curable whatever the ‘risk’ or ‘stage’
It doesn’t seem to matter which regimen you choose as long as it works and you are familiar with it!
‘Specialist’ center skills may be more important than the actual therapy
But - occasional patients still die despite multiple chemotherapy and surgical interventions
![Page 29: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/29.jpg)
![Page 30: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/30.jpg)
![Page 31: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/31.jpg)
![Page 32: State of the Art: Gestational Trophoblastic Lesions](https://reader035.vdocuments.site/reader035/viewer/2022062217/56815915550346895dc64137/html5/thumbnails/32.jpg)
Methotrexate in high riskGTN (Sheffield, UK 1973-86)
AVC - dactinomycin, vincristine, cyclophosphmide
Median follow-up 24y
22MTX
12 4Other
Resistance
AVC
6 (27%)CR
20 Alive and well3 + 11
2†Late deaths 0
2nd malignancies 0